Genetek LifeSciences to start remdesivir production in Wardha

Published On 2021-04-28 03:30 GMT   |   Update On 2021-04-28 09:27 GMT

New Delhi: Union minister Nitin Gadkari on Tuesday said Genetek LifeSciences will start production of remdesivir injections, used in the treatment of Covid-19, in Wardha (Maharashtra) from Wednesday. While speaking to reporters during the inauguration of a Covid-care centre in Nagpur, Gadkari said the company will produce 30,000 vials per day.Remdesivir is approved in India for...

Login or Register to read the full article

New Delhi: Union minister Nitin Gadkari on Tuesday said Genetek LifeSciences will start production of remdesivir injections, used in the treatment of Covid-19, in Wardha (Maharashtra) from Wednesday.

While speaking to reporters during the inauguration of a Covid-care centre in Nagpur, Gadkari said the company will produce 30,000 vials per day.

Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory confirmed Covid-19 in adults and children hospitalised with severe disease.
Genetek LifeSciences, based in Wardha, has received loan licence to manufacture remdesivir injections.
A team from Hyderabad has reached Wardha and the trials are underway and the production is expected to start from Wednesday, the minister said.
The remdesivir injections will be distributed in Nagpur and other districts of Vidarbha.
Similarly, it will be distributed in parts of Maharashtra as per the requirement and it will address the shortage of remdesivir injection.
Gadkari also talked about steps taken to streamline oxygen supply in Nagpur and also expressed confidence that the recovery situation will improve more in coming few days.
Gadkari was accompanied with BJP leader Devendra Fadnavis during the visit.



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News